New Compounds

Abstract

The novel optically pure compounds Na + , Mg 2+ , Li + , K + , Ca 2+ and N + (R) 4 salts of (+)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole or (−)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole, in particular sodium and magnesium salt form thereof, where R is an alkyl with 1-4 carbon atoms, processes for the preparation thereof and pharmaceutical preparations containing the compounds as active ingredients, as well as the use of the compounds in pharmaceutical preparations and intermediates obtained by preparing the compounds.

1 - 34 . (canceled) 
   
   
       35 . An optically pure potassium salt of (−)-5-methoxy-2-[[(4-methoxy-3,5,dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole. 
   
   
       36 . The compound according to  claim 35 , wherein the compound is crystalline. 
   
   
       37 . Potassium salt of (−)-5-methoxy-2-[[(4-methoxy-3,5,dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole in an optical purity of at least about 94% enantiomeric excess. 
   
   
       38 . The compound according to  claim 37 , when the optical purity is at least 94% enantiomeric excess. 
   
   
       39 . The compound according to  claim 37 , wherein the compound is in crystalline form. 
   
   
       40 . The compound according to  claim 38 , wherein the compound is in crystalline form. 
   
   
       41 . Potassium salt of (−)-5-methoxy-2-[[(4-methoxy-3,5,dimethyl-2-pyridinyl)methyl]-sulfinyl]-1H-benzimidazole in an optical purity of at least about 99.8% enantiomeric excess. 
   
   
       42 . The compound according to  claim 41 , wherein the optical purity is at least 99.8% enantiomeric excess. 
   
   
       43 . The compound according to  claim 41 , wherein the compound is in crystalline form. 
   
   
       44 . The compound according to  claim 42 , wherein the compound is in crystalline form. 
   
   
       45 . A pharmaceutical formulation for administration comprising the potassium salt of any one of the preceding claims and a pharmaceutically acceptable carrier.